A novel mortality risk score for emphysematous pyelonephritis: A multicenter study of the Global Research in the Emphysematous Pyelonephritis group

Nenhuma Miniatura disponível
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
TRUJILLO-SANTAMARIA, Hegel
ROBLES-TORRES, Jose Ivan
TEOH, Jeremy Yuen-Chun
TANIDIR, Yiloren
CAMPOS-SALCEDO, Jose Gadu
BRAVO-CASTRO, Edgar Ivan
WROCLAWSKI, Marcelo Langer
YEOH, W. S.
KUMAR, Santosh
SANCHEZ-NUNEZ, Juan Eduardo
Citação
CURRENT UROLOGY, v.18, n.1, p.55-60, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Emphysematous pyelonephritis (EPN) is a necrotizing infection of the kidney and the surrounding tissues associated with considerable mortality. We aimed to formulate a score that classifies the risk of mortality in patients with EPN at hospital admission.Materials and methods: Patients diagnosed with EPN between 2013 and 2020 were retrospectively included. Data from 15 centers (70%) were used to develop the scoring system, and data from 7 centers (30%) were used to validate it. Univariable and multivariable logistic regression analyses were performed to identify independent factors related to mortality. Receiver operating characteristic curve analysis was performed to construct the scoring system and calculate the risk of mortality. A standardized regression coefficient was used to quantify the discriminating power of each factor to convert the individual coefficients into points. The area under the curve was used to quantify the scoring system performance. An 8-point scoring system for the mortality risk was created (range, 0-7).Results: In total, 570 patients were included (400 in the test group and 170 in the validation group). Independent predictors of mortality in the multivariable logistic regression were included in the scoring system: quick Sepsis-related Organ Failure Assessment score >= 2 (2 points), anemia, paranephric gas extension, leukocyte count >22,000/mu L, thrombocytopenia, and hyperglycemia (1 point each). The mortality rate was <5% for scores <= 3, 83.3% for scores 6, and 100% for scores 7. The area under the curve was 0.90 (95% confidence interval, 0.84-0.95) for test and 0.91 (95% confidence interval, 0.84-0.97) for the validation group.Conclusions: Our score predicts the risk of mortality in patients with EPN at presentation and may help clinicians identify patients at a higher risk of death.
Palavras-chave
Emphysematous pyelonephritis, Mortality, Prognosis
URI
https://observatorio.fm.usp.br/handle/OPI/58282
Referências
  1. Abdul-Halim H, 2005, UROL INT, V75, P123, DOI 10.1159/000087165
  2. Al-Geizawi SMT, 2010, TRANSPL INFECT DIS, V12, P543, DOI 10.1111/j.1399-3062.2010.00538.x
  3. Arrambide-Herrera JG, 2022, ACTAS UROL ESP, V46, P98, DOI [10.1016/j.acuroe.2021.01.010, 10.1016/j.acuro.2021.01.007]
  4. Aswathaman K, 2008, UROLOGY, V71, P1007, DOI 10.1016/j.urology.2007.12.095
  5. Cappellini MD, 2015, SEMIN HEMATOL, V52, P261, DOI 10.1053/j.seminhematol.2015.07.006
  6. Delanaye P, 2017, NEPHRON, V136, P302, DOI 10.1159/000469669
  7. Falagas ME, 2007, J UROLOGY, V178, P880, DOI 10.1016/j.juro.2007.05.017
  8. Franchini M, 2017, EXPERT REV HEMATOL, V10, P99, DOI 10.1080/17474086.2017.1271319
  9. Gill TM, 2012, JAMA-J AM MED ASSOC, V307, P199, DOI 10.1001/jama.2011.1992
  10. Hsueh PR, 2010, J MICROBIOL IMMUNOL, V43, P452, DOI 10.1016/S1684-1182(10)60070-9
  11. HUANG JJ, 1991, J UROLOGY, V146, P148, DOI 10.1016/S0022-5347(17)37736-4
  12. Huang JJ, 2000, ARCH INTERN MED, V160, P797, DOI 10.1001/archinte.160.6.797
  13. Khaira A, 2009, INT UROL NEPHROL, V41, P959, DOI 10.1007/s11255-009-9552-y
  14. Klatte T, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1419-1
  15. Krishnamoorthy S, 2021, BJU INT, V127, P418, DOI 10.1111/bju.15225
  16. LANGSTON C S, 1970, American Journal of Roentgenology Radium Therapy and Nuclear Medicine, V110, P778
  17. Lu YC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-418
  18. MICHAELI J, 1984, J UROLOGY, V131, P203, DOI 10.1016/S0022-5347(17)50309-2
  19. Olvera-Posada D, 2014, UROLOGY, V83, P1280, DOI 10.1016/j.urology.2014.02.010
  20. Riley LK, 2015, AM FAM PHYSICIAN, V92, P1004
  21. SCHAINUCK LI, 1968, AM J MED, V44, P134, DOI 10.1016/0002-9343(68)90245-3
  22. Shakya A, 2020, CURR DIABETES REV, V16, P104, DOI 10.2174/1573399815666190510112035
  23. Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
  24. Tang Hung-Jen, 2001, Journal of Microbiology Immunology and Infection, V34, P125
  25. Ubee SS, 2011, BJU INT, V107, P1474, DOI 10.1111/j.1464-410X.2010.09660.x
  26. Wan YL, 1998, J UROLOGY, V159, P369, DOI 10.1016/S0022-5347(01)63919-3
  27. Yap XH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52989-7

Coleções
Artigos e Materiais de Revistas Científicas - HC/Outros